Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of incretin analogs as new therapeutics for Friedreich's Ataxia
2014-003598-41Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Sep 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of exenatide and liraglutide in Friedreich ataxia (FA) (2 arms), sponsored by Erasmus Hospital. Primary endpoints: Frataxin expression change and Safety and tolerability. Started Sep 2014; status: completed.
02
Drugs
exenatideliraglutide
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2014-003598-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003598-41.